Swiss eyecare firm Alcon has made a move to boost its position in ophthalmological medicines with a $15.25 per share offer to buy Aerie Pharmaceuticals in a transaction that values the U
Novartis and eyecare spinout Alcon have agreed to settle bribery charges brought by the US federal authorities, focused on activities in Greece and other countries, for $347 mi
Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products.
Novartis’ ophthalmology division Alcon has announced plans to build a digital platform to streamline, simplify and improve cataract surgery for surgeons and patients.
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.